EMPOWER: Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia (clinicaltrials.gov) - Sep 23, 2026 - P4 | N=113 | Completed | Sponsor: University Hospital, Basel, Switzerland | Recruiting ➔ Completed
Trial completion • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hepatology • Liver Failure • Renal Disease
|